Identification of biomarkers that predict responsiveness to Dupilumab among severe asthma
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Pharmacodynamics
- 06 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 29 Sep 2021 Planned End Date changed from 31 Mar 2021 to 31 Mar 2022.
- 01 Oct 2020 New trial record